Table 3.
AE, n (%) | Single-dose phase | Multiple-dose phase | ||||||
---|---|---|---|---|---|---|---|---|
AQW051, mg | Placebo | AQW051, mg | Placebo | |||||
2.5 (N = 6) | 15 (N = 6) | 75 (N = 6) | (N = 6) | 2.5 (N = 18) | 15 (N = 18) | 75 (N = 12) | (N = 16) | |
Any | 3 (50.0) | 2 (33.3) | 2 (33.3) | 1 (16.7) | 12 (66.7) | 5 (27.8) | 8 (66.7) | 4 (25.0) |
Abnormal dreams | 0 | 0 | 0 | 0 | 2 (11.1) | 0 | 0 | 0 |
Constipation | 1 (16.7) | 0 | 0 | 0 | 2 (11.1) | 0 | 0 | 0 |
Diarrhoea | 1 (16.7) | 0 | 0 | 1 (16.7) | 2 (11.1) | 0 | 0 | 0 |
Dizziness | 0 | 0 | 1 (16.7) | 0 | 3 (16.7) | 1 (5.6) | 2 (16.7) | 0 |
Dizziness postural | 0 | 0 | 0 | 0 | 2 (11.1) | 0 | 0 | 0 |
Headache | 0 | 2 (33.3) | 0 | 0 | 2 (11.1) | 2 (11.1) | 2 (16.7) | 1 (6.3) |
Nausea | 0 | 0 | 0 | 0 | 4 (22.2) | 0 | 1 (8.3) | 0 |
Pharyngolaryngeal pain | 0 | 0 | 0 | 0 | 2 (11.1) | 0 | 1 (8.3) | 1 (6.3) |
Somnolence | 0 | 0 | 0 | 0 | 2 (11.1) | 0 | 1 (8.3) | 1 (6.3) |